Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Aerovate Therapeutics, Inc. (Note: The input metadata references "Jade Biosciences, Inc.", but the filing text explicitly identifies the registrant as Aerovate Therapeutics, Inc.) on June 5, 2024. The record date for the meeting was April 12, 2024, with 28,737,381 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Proposal 1 (Election of Directors): Stockholders approved the election of David Grayzel, M.D., and Maha Katabi, Ph.D., as Class III directors.
- David Grayzel, M.D.: 24,399,034 votes For; 1,489,651 votes Withheld; 2,185,964 Broker Non-Votes.
- Maha Katabi, Ph.D.: 25,853,289 votes For; 37,357 votes Withheld; 2,184,003 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Results: 28,074,033 votes For; 511 votes Against; 105 votes Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the correct registrant name is Aerovate Therapeutics, Inc. (AVTE), not Jade Biosciences, Inc.
- Confirm the successful ratification of KPMG LLP as the independent auditor for the 2024 fiscal year.
- Note the significant number of broker non-votes (approx. 2.18 million) on the director election proposals, indicating shares held by brokers that were not voted on these matters.
- Review the Definitive Proxy Statement filed on April 26, 2024, for detailed biographies of the newly elected directors and further governance context.